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INTRODUCTION
Defects in insulin secretion and aggravation of insulin 
resistance are considered the primary factors affecting 
diabetes development and progression. However, apart 
from insulin itself, various other factors may also affect 
glucose regulation in diabetes [1,2]. One of these factors 
may be the dysregulation of glucagon upon pancreatic 
α-cell dysfunction [3-5]. By enhancing gluconeogenesis 
in the liver, glucagon levels are elevated upon fasting to 
prevent hypoglycemia [6-8]. The secretory mechanism 
of glucagon from α-cells has been proposed to be reg-
ulated by insulin concentrations from β-cells, which 
are located closely to α-cells [9,10]. From a theoretical 
view, when insulin secretion increases after meals, glu-
cagon secretion must be suppressed [11-13]. However, 
this mechanism appears to be dysregulated in diabetic 
patients who show relatively higher postprandial glu-
cagon levels than normal subjects [14,15]. This suggests 
that α-cell resistance or dysfunction may be present in 
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Background/Aims: The importance of α-cell dysfunction in the pathogenesis 
of type 2 diabetes has re-emerged recently. However, data on whether relative 
glucagon excess is present in clinical settings are scarce. We aimed to investi-
gate associations between glucagon-to-insulin ratio and various metabolic pa-
rameters.
Methods: A total of 451 patients with type 2 diabetes naïve to insulin treatment 
were recruited. Using glucagon-to-insulin ratio, we divided subjects into quar-
tiles according to both fasting and postprandial glucagon-to-insulin ratios. 
Results: The mean age of the subjects was 58 years, with a mean body mass 
index of 25 kg/m2. The patients in the highest quartile of glucagon-to-insulin 
ratio had higher glycated hemoglobin (HbA1c) levels. HbA1c levels were posi-
tively correlated with both fasting and postprandial glucagon-to-insulin ratios. 
Subjects in the highest quartile of postprandial glucagon-to-insulin ratio were 
more likely to exhibit uncontrolled hyperglycemia, even after adjusting for 
confounding factors (odds ratio, 2.730; 95% confidence interval, 1.236 to 6.028; p 
for trend < 0.01). 
Conclusions: Hyperglucagonemia relative to insulin could contribute to un-
controlled hyperglycemia in type 2 diabetes patients. 
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patients with diabetes [4,5,16]. 
In this aspect, Unger [17] has suggested the ‘bihor-
monal-abnormality’ hypothesis in regards to the devel-
opment of diabetes, stating that both relative or abso-
lute hyperglucagonemia and insulin deficiency may be 
present in diabetic subjects. Recently, both insulin and 
glucagon have received attention as critical controllers 
of blood glucose levels [18-21]. Interestingly, in patients 
with pancreatic cancer, glucagon-to-insulin ratio after a 
75-g oral glucose challenge was independently correlated 
with glycated hemoglobin (HbA1c) levels [22]. These re-
sults suggested that relative hyperglucagonemia might 
influence hyperglycemia in diabetes and that modulat-
ing the activity of glucagon might be a promising target 
for achieving glycemic control in a subgroup of diabetic 
patients [23,24]. Nevertheless, data on increases in gluca-
gon relative to insulin and their associations with other 
clinical parameters are scarce. 
In this study, we evaluated whether increases in glu-
cagon relative to insulin (glucagon-to-insulin ratio) are 
associated with various metabolic parameters and as-
sessed the contributions of relative hyperglucagonemia 
on blood glucose control. 
METHODS
Study design and population 
Type 2 diabetes mellitus (DM) patients who visited 
the outpatient clinic at the endocrinology department 
of Gangnam Severance Hospital in Seoul, Korea from 
March 2012 to January 2013 were registered (n = 533; 342 
men, 191 women). The study subjects underwent routine 
blood tests to assess insulin and glucagon levels both 
before and 2 hours after a meal. This study was approved 
by the local Institutional Review Board (IRB approval 
number: 3-2014-0169). Subjects with gestational diabetes 
or type 1 DM or who had been treated with insulin were 
excluded from the study. We divided the study popula-
tion (n = 451; 308 men, 143 women) into quartiles of the 
same number of patients according to both fasting and 
postprandial glucagon-to-insulin ratios, respectively.
Biochemical measurement 
Plasma glucose was measured by the glucose oxidase 
method using a 747 Automatic Analyzer (Hitachi, To-
kyo, Japan). The levels of total cholesterol, high densi-
ty lipoprotein cholesterol (HDL-C), triglycerides, and 
alanine aminotransferase (ALT) were evaluated by an 
enzymatic colorimetric method (Hitachi 747, Daiichi, 
Tokyo, Japan). Low density lipoprotein cholesterol con-
tent was calculated according to the Friedewald formula 
[25]. HbA1c levels were measured by high-performance 
liquid chromatography (Cobas Integra 800, Roche, 
Mannheim, Germany). Insulin and glucagon levels were 
measured using a radioimmunoassay method (Roche 
Diagnostics for insulin; MP Biomedicals, Irvine, CA, 
USA for glucagon).
Statistical analysis
Continuous variables are presented as the mean ± stan-
dard deviation (SD) and categorical variables as absolute 
numbers (percentage). The significance of differences in 
glucagon-to-insulin ratio quartiles was analyzed using 
either the one-way analysis of variance, the chi-square 
test, or Fisher exact test as appropriate. The degree of 
correlation between metabolic parameters and gluca-
gon-to-insulin ratio was presented by Pearson correla-
tion coefficient (r). Independent predictors of gluca 
gon-to-insulin ratio were assessed by multiple stepwise 
linear regression analyses and logistic regression mod-
els were used to determine the odds ratio (OR) of the 
covariates. All statistical analyses were performed using 
SPSS version 20.0 (IBM Co., Armonk, NY, USA), and p 
values < 0.05 were considered statistically significant.
Ethical standard 
This human study has been reviewed by the appropriate 
ethics committee and has therefore been performed in 
accordance with the ethical standards stipulated in the 
1964 Declaration of Helsinki and its following amend-
ments.
Human and animal rights disclosure
All procedures followed were in accordance with the 
ethical standards of the responsible committee on hu-
man experimentation (institutional and national) and 
with the Helsinki Declaration of 1975, as revised in 2008.
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RESULTS
Clinical and biochemical characteristics of the study 
population
The mean age of the whole study population was 57.7 ± 
12.7 years, and the mean duration of diabetes was 8.7 ± 
7.8 years. The mean HbA1c level was 6.96% ± 1.20% (52.53 
± 13.13 mmol/mol), and the mean body mass index (BMI) 
was 24.98 ± 3.29 kg/m2. Patients in the highest quartiles 
of both fasting and postprandial glucagon-to-insulin 
ratios had the highest HbA1c levels (7.19% ± 1.47%, p = 
0.02 for fasting; and 7.28% ± 1.57%, p < 0.01 for postpran-
dial glucagon-to-insulin ratio, respectively) and tended 
to have the longest duration of diabetes (10.0 ± 8.1 years, 
p = 0.07 for fasting; and 11.0 ± 9.2 years, p < 0.01 for post-
prandial glucagon-to-insulin ratio, respectively). These 
patients also had lower BMI and ALT levels, as well as 
a higher HDL-C levels, than the other groups (Tables 1 
and 2).
Association between metabolic parameters and 
glucagon-to-insulin ratio
Correlations between metabolic parameters and fast-
ing or postprandial glucagon-to-insulin ratio were an-
alyzed. Both fasting and postprandial glucose, HbA1c 
and HDL-C levels were positively correlated with fasting 
glucagon-to-insulin ratio, whereas BMI, triglycerides, 
and ALT levels showed negative correlations. Duration 
of diabetes, HbA1c, and HDL-C were positively correlat-
ed with postprandial glucagon-to-insulin ratio; BMI, 
triglycerides, and ALT showed a negative correlation 
with postprandial glucagon-to-insulin ratio (Table 3).
Independent factors associated with fasting and 
postprandial glucagon-to-insulin ratios
We analyzed independent factors associated with both 
fasting and postprandial glucagon-to-insulin ratios. 
HbA1c, BMI, and ALT were independent factors asso-
ciated with fasting glucagon-to-insulin ratio. The post-
prandial glucagon-to-insulin ratio was significantly 
and independently associated with HbA1c, duration of 
diabetes, BMI, and ALT. In both fasting and postpran-
dial states, elevation of HbA1c levels was independently 
associated with higher fasting and postprandial gluca-
gon-to-insulin ratios (regression coefficient = 1.92, stan-
dardized error = 0.43, p < 0.01 for fasting; and regression 
coefficient = 0.38, standardized error = 0.11, p < 0.01 for 
postprandial glucagon-to-insulin ratio) (Table 4).
Association of glucagon-to-insulin ratio with the 
risk of uncontrolled blood glucose 
To assess the risk of uncontrolled blood glucose levels 
with respect to glucagon-to-insulin ratio, we performed 
multiple logistic regression analysis. After adjusting for 
age, sex, BMI, HDL-C, and ALT, subjects in the highest 
quartile of postprandial glucagon-to-insulin ratio were 
3.7-fold more likely to have uncontrolled diabetes, de-
fined by HbA1c ≥ 7.5% (58.5 mmol/mol) (OR, 3.681; 95% 
confidence interval [CI], 1.752 to 7.736; p for trend < 0.01). 
Moreover, subjects in the highest quartile of postpran-
dial glucagon-to-insulin ratio were 2.7-fold more likely 
to have a higher HbA1c level, even after further adjusting 
for the duration of diabetes and the use of metformin, 
sulfonylurea, and dipeptidyl peptidase-4 inhibitor (DPP- 
4 I) (OR, 2.730; 95% CI, 1.236 to 6.028; p for trend < 0.01) 
(Table 5). In a model adjusting for age, sex, BMI, HDL-C, 
ALT, duration of diabetes, and use of metformin, sul-
fonylurea, and DPP-4 I, ORs for uncontrolled diabetes 
increased gradually with higher quartiles of postpran-
dial glucagon-to-insulin ratio (OR, 0.739; 95% CI, 0.321 
to 1.701 for Quartile 2; OR, 2.041; 95% CI, 0.946 to 4.405 
for Quartile 3; and OR, 2.730; 95% CI, 1.236 to 6.028 for 
Quartile 4, respectively) (Table 5, Fig. 1).
DISCUSSION
In this study, we found that patients with a higher 
glucagon-to-insulin ratio upon fasting or in a post-
prandial state exhibit worse blood glucose control (i.e., 
higher HbA1c levels). Both fasting and postprandial 
glucagon-to-insulin ratios were found to be positively 
correlated with HbA1c and HDL-C levels, whereas they 
were negatively correlated with ALT. Interestingly, ORs 
for higher HbA1c levels increased gradually with in-
creasing quartiles of postprandial glucagon-to-insulin 
ratio, demonstrating that glucagon-to-insulin ratio re-
flects persistent, but gradual, degrees of glycemic con-
trol across the whole DM population, rather than there 
being an abrupt cut-off value of glucagon that indicates 
glycemic control in an all-or-none fashion. Our results 
suggest that an increased level of glucagon, relative to 
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insulin, is closely associated with poor glycemic control. 
Our study highlighted glucagon excess relative to in-
sulin in a postprandial state as being associated with 
poor glycemic control. Previously, several studies sug-
gested that absolute or relative hyperglucagonemia may 
be a cause of poor glycemic control in subjects with im-
paired glucose tolerance or diabetes [13,16,26-30]. How-
ever, most of these studies were performed in a small 
number of subjects, and no study has explored what 
features are associated with relative glucagon excess 
[11,16,28,31,32]. Overcoming these limitations, we have 
demonstrated in a relatively large number of subjects (n 
= 451) that relative glucagon excess is associated with var-
ious metabolic parameters in clinical practice. 
We initially hypothesized that subjects with relative 
glucagon excess might be associated with poor glyce-
mic control, together with both insulin resistance and 
worse metabolic parameters [11,15,33,34]. Interestingly, 
we found that subjects with higher glucagon-to-insu-
lin ratio had lower BMI and higher HDL despite poor 
Table 3. Associations between metabolic parameters and glucagon-to-insulin ratio 
Variable
Fasting Postprandial 
r p value r p value
Age, yr 0.03 0.55 0.04 0.43 
Duration of diabetes, yr 0.06 0.24 0.11 0.02 
Body mass index, kg/m2 –0.29 < 0.01 –0.22 < 0.01
Fasting plasma glucose, mg/dL 0.15 < 0.01 0.07 0.12 
Postprandial glucose, mg/dL 0.12 0.01 –0.05 0.27 
HbA1c, % 0.20 < 0.01 0.15 < 0.01
Total cholesterol, mg/dL 0.00 0.96 –0.04 0.40 
Triglyceride, mg/dL –0.10 0.03 –0.10 0.04 
HDL-C, mg/dL 0.12 0.01 0.13 0.01 
LDL-C, mg/dL 0.04 0.42 –0.01 0.83 
ALT, IU/L –0.16 < 0.01 –0.18 < 0.01
Values are presented as Pearson’s correlation coefficient (r). A p < 0.05 was regarded as statistically significant.
HbA1c, glycated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ALT, 
alanine aminotransferase. 
Table 4. Independent factors associated with glucagon-to-insulin ratio
Variable
Multi-variate regression analysis
Fasting Postprandial
Regression
 coefficient
SE p value R2
Regression
 coefficient
SE p value R2
Duration of diabetes, yr 0.03 0.07 0.68 0.14 0.03 0.02 0.05 0.12 
Body mass index, kg/m2 –0.79 0.16 < 0.01 0.14 –0.13 0.04 < 0.01 0.12 
HbA1c, % 1.92 0.43 < 0.01 0.14 0.38 0.11 < 0.01 0.12 
HDL-C, mg/dL 0.08 0.05 0.12 0.14 0.02 0.01 0.06 0.12 
ALT, IU/L –0.06 0.03 0.02 0.14 –0.02 0.01 0.01 0.12 
Metformin medication –1.39 1.28 0.28 0.14 –0.57 0.31 0.07 0.12 
Sulfonylurea medication 1.23 1.23 0.32 0.14 0.24 0.30 0.43 0.12 
DPP-4 I medication –1.04 1.10 0.34 0.14 –0.38 0.27 0.16 0.12 
Values are presented as regression coefficient and standard error. A p < 0.05 was regarded as statistically significant.
SE, standard error; HbA1c, glycated hemoglobin; HDL-C, high density lipoprotein cholesterol; ALT, alanine aminotransferase; 
DPP-4 I, dipeptidyl peptidase-4 inhibitor. 
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glycemic control (higher HbA1c levels). The characteris-
tics of our study group seem to be in line with those of 
non-obese Asian diabetic patients with islet dysfunction 
[30,35]. A previous study showed that lean patients with 
type 2 diabetes can exhibit better lipid profile than obese 
patients, even though the lean patients have more un-
controlled hyperglycemia [36]. Lower BMI is normally 
accompanied with better metabolic profile [37]. Howev-
er, in non-obese patients with type 2 diabetes, BMI with 
insulin resistance is not the major determinant of glyce-
mic control [38]. Thus, there could have been a discrep-
ancy between metabolic profiles and glycemic control 
in our study population [36]. In these individuals, β-cell 
dysfunction, reflected as insulin deficiency, rather than 
insulin resistance, may be the dominant factor for un-
controlled hyperglycemia [38]. In addition to this, we as-
sume that not only β-cell hypofunction but also relative 
α-cell hyperfunction may contribute to poor glycemic 
control in this study population. Several papers have 
found glucagon excess to be an independent pathogen-
esis from insulin resistance in type 2 diabetes [13,39,40], 
and hyperglucagonemia has been continually detected 
in diabetic patients without obesity [31]. Additionally, 
a previous study found decreased β-cell and increased 
α-cell mass in pancreatic islets of Korean type 2 diabe-
tes patients with a BMI less than 25 kg/m2 [30]. In the 
present study, we noted that glucagon-to-insulin ratio 
exhibited an increasing tendency as the duration of di-
Table 5. Odds ratio for uncontrolled hyperglycemia (HbA1c ≥ 7.5%).
Variable Quartile 1 (n = 112) Quartile 2 (n = 113) Quartile 3 (n = 113) Quartile 4 (n = 113) p for trend
Fasting glucagon-to-insulin ratio (n = 451)
Model 1a 1.00 (reference) 0.451 (0.230–0.885) 0.552 (0.289–1.055) 1.080 (0.602–1.939) 0.65
Model 2b 1.00 (reference) 0.470 (0.239–0.927) 0.582 (0.303–1.117) 1.166 (0.642–2.119) 0.49
Model 3c 1.00 (reference) 0.468 (0.232–0.944) 0.734 (0.366–1.474) 1.539 (0.772–3.070) 0.13
Model 4d 1.00 (reference) 0.388 (0.184–0.818) 0.566 (0.270–1.188) 1.317 (0.631–2.749) 0.33
Postprandial glucagon-to-insulin ratio (n = 451)
Model 1a 1.00 (reference) 0.799 (0.381–1.678) 1.888 (0.981–3.633) 2.248 (1.179–4.283) < 0.01
Model 2b 1.00 (reference) 0.874 (0.411–1.855) 1.991 (1.029–3.856) 2.391 (1.245–4.592) < 0.01
Model 3c 1.00 (reference) 0.902 (0.407–1.999) 2.902 (1.394–6.042) 3.681 (1.752–7.736) < 0.01
Model 4d 1.00 (reference) 0.739 (0.321–1.701) 2.041 (0.946–4.405) 2.730 (1.236–6.028) < 0.01
Values are presented as odds ratios with the lowest quartile group of glucagon/insulin ratio as a reference. A p for trend < 0.05 
was regarded as statistically significant.
HbA1c, glycated hemoglobin. 
aModel 1, not adjusted.
bModel 2, adjusted for age and sex. 
cModel 3, adjusted for age, sex, body mass index (BMI), high density lipoprotein cholesterol (HDL-C), and alanine aminotrans-
ferase (ALT). 
dModel 4, adjusted for age, sex, BMI, HDL-C, ALT, duration of diabetes, metformin medication, sulfonylurea medication, and 
dipeptidyl peptidase-4 inhibitor medication. 
Quartile 1
Quartile 2
Quartile 3
Quartile 4
OR (95% CI)
0 1 2 3 4 5 6 7
Figure 1. Odds ratio for glycated hemoglobin ≥ 7.5% accord-
ing to postprandial glucagon-to-insulin ratio quartiles. Lo-
gistic regression was used for calculating odds ratios (ORs) 
with 95% confidence intervals (CIs). The reference group 
comprised patients in the lowest quartile of postprandial 
glucagon-to-insulin ratio (Quartile 1). Adjusted for age, sex, 
body mass index, high density lipoprotein cholesterol, ala-
nine aminotransferase, duration of diabetes, and metformin, 
sulfonylurea, and dipeptidyl peptidase-4 inhibitor use.
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abetes became longer. This implies that overall islet cell 
dysfunction becomes worse as type 2 diabetes progress-
es. Therefore, our study suggests that, in patients with 
lower BMI and long-standing type 2 diabetes, strategies 
to suppress glucagon excess together with promoting 
insulin secretion may be helpful. 
The relationship between glucagon-to-insulin ratio 
and HbA1c has been rarely studied. Jin et al. [22] showed 
a linear association between glucagon-to-insulin ratio 
and HbA1c in subjects with pancreatic cancer, a tenden-
cy which was similar to that in our study of data for type 2 
diabetic subjects. In our study, we further demonstrated 
that glucagon-to-insulin ratio is a significant determi-
nant of glycemic control. The OR of postprandial gluca-
gon-to-insulin ratio followed a significantly increasing 
trend in analysis of p for trend. Also, interestingly, the 
general shape of ORs followed a J-shape, with postpran-
dial glucagon-to-insulin ratios in quartile 2 < quartile 1 
and those in quartiles 3 and 4 > quartile 1. The possible 
reasons for this J-shaped association between the glyce-
mic control and the glucagon-to-insulin ratio could be 
the result of unique clinical characteristics in quartile 2, 
such as higher age and higher DPP-4 I use, compared to 
the other quartiles.
This study is not without limitations. Most of the 
study subjects were from urban areas and had generally 
well-controlled glucose levels, which may not represent 
the entire diabetic population. This study also has the 
general limitation of being cross-sectional study, and 
thus, it cannot demonstrate whether there is a causal re-
lationship between glucose control and glucagon-to-in-
sulin ratio. Postprandial glucagon and insulin in this 
study were not measured after oral glucose tolerance 
test but after a normal meal, which means calorie and 
nutrient intakes may have varied from subject to subject. 
In addition, study subjects with various medications, 
such as metformin, sulfonylurea, and DPP-4 I, could be 
another limitation as well, because these medications 
might affect serum levels of insulin and glucagon. How-
ever, statistical significance was still prominent even 
after adjusting for all three medications, and this may 
also strengthen our main findings. Conversely, our data 
may reflect “everyday” changes in glucagon, insulin, and 
glucose in actual clinical practice.
In summary, type 2 diabetes patients with higher 
glucagon-to-insulin ratios, especially in a postprandial 
state, were more likely to show uncontrolled hypergly-
cemia. Accordingly, we suggest that different treatment 
approaches may be needed for subjects with relatively 
lower BMI, less insulin resistance, and dysregulated glu-
cagon levels, compared to patients with higher BMI and 
more insulin resistance. Instead of concentrating on im-
provements in insulin resistance, a strategy to suppress 
glucagon together with increasing insulin secretion may 
be another key therapeutic option for treating type 2 di-
abetic patients in the future. Understanding the diverse 
pathogenesis of hyperglycemia may help to personalize 
treatment strategies in type 2 diabetes. Larger studies to 
investigate the effect of glucagon together with the ac-
tion of insulin are warranted. 
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